UPC — Universe Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $2.24m
- -$22.09m
- $17.86m
- 53
- 82
- 27
- 55
Annual balance sheet for Universe Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | R2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 21.8 | 18.9 | 6.65 | 30.9 | 33.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 15.6 | 15.2 | 11.6 | 17 | 14.2 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 50.5 | 41.5 | 25.3 | 51.6 | 53.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.4 | 13.6 | 12.8 | 13.1 | 12.5 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 70.1 | 59.5 | 41.7 | 68 | 69.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.2 | 13.1 | 13.8 | 20.3 | 13.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 11.2 | 13.1 | 13.8 | 22.5 | 13.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 58.9 | 46.4 | 28 | 45.5 | 56.1 |
| Total Liabilities & Shareholders' Equity | 70.1 | 59.5 | 41.7 | 68 | 69.3 |
| Total Common Shares Outstanding |